Proactive Investors - Run By Investors For Investors

Summit Therapeutics to kick off gonorrhoeae trial next year

Identified using the company’s Discuva Platform, the new drug is designed to exploit the N. gonorrhoeae target
Summit Therapeutics to kick off gonorrhoeae trial next year
Cases of the sexually transmitted disease are on the rise

Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT) said it will kick off a Phase I clinical trial of a new antibiotic for gonorrhoea in the second half of next year.

It follows the nomination of SMT-571 as its lead candidate to tackle the sexually transmitted infection.

READ: Summit Therapeutics awarded additional US$12mln under contract with US BARDA

Identified using the company’s Discuva Platform, it is designed to exploit the N. gonorrhoeae target.

The study itself will be supported by the US$4.5mln it received from CARB-X, a US programme designed to accelerate the development of new antibiotics.

The need for new treatments for gonorrhoea was laid bare last week when the Centers for Disease Control and Prevention showed that cases of the STI had increased by 67% between 2013 and 2017.

Worrying also was the rise in drug-resistant strains of the infection.

“We believe our new science and new way of thinking together enable our goal to develop the right drug for the right pathogen and create opportunities for success,” said Dr David Roblin, Summit’s head of R&D of Summit.

“SMT-571 is being developed specifically for gonorrhoea, meaning that it is designed to have both a targeted spectrum of activity and be tailored to meet the needs of patients with gonorrhoea.”

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

pills
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
man and woman working in a lab
October 11 2018
There were no adverse safety findings and excellent drug-like properties were confirmed.
scientist in lab
September 25 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use